Product Description

Docetaxel is a microtubule depolymerization inhibitor. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity.

Screeningbio‘s A549/Docetaxel resistance cell line generated by exposing to increasing concentration of drug for certain period of time. After stable acquire resistance, cells were harvested and characterized for drug resistance by 7 days proliferation assay.

Data

Target Background

Docetaxel (Taxotere) is a semisynthetic taxane chemotherapeutic agent that stabilizes microtubules and inhibits mitotic spindle disassembly, leading to cell cycle arrest at the G2/M phase and apoptosis in rapidly dividing cancer cells. Compared to paclitaxel, docetaxel exhibits higher affinity for β‑tubulin and is more potent in certain tumor types. It is widely used in the treatment of breast, prostate, non‑small cell lung, gastric, and head/neck cancers. However, the development of drug resistance remains a major challenge limiting its long‑term efficacy.

Mechanistically, docetaxel resistance arises through multiple cellular adaptations. Alterations in β‑tubulin isotypes (e.g., overexpression of class III β‑tubulin, TUBB3) or mutations at the taxane‑binding site reduce drug binding affinity, while upregulation of efflux transporters such as P‑glycoprotein (MDR1/ABCB1) decreases intracellular drug accumulation. Additionally, activation of survival pathways—including PI3K/Akt, MAPK, and NF‑κB signaling—promotes anti‑apoptotic responses.

Changes in microtubule‑associated proteins (MAPs, e.g., tau and MAP4) and enhanced autophagy or epithelial–mesenchymal transition (EMT) also contribute to reduced drug sensitivity.

Understanding these mechanisms is critical for designing strategies to overcome resistance, such as combination therapy with efflux inhibitors, targeting compensatory signaling networks (e.g., PI3K/Akt inhibitors), or employing patient‑derived resistant cell models to guide personalized therapy development.